{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jiang C"],"funding":["BMHB | Capital Health Research and Development of Special Fund","Ministry of Science and Technology of the People's Republic of China","Beijing Municipal Health Commission","Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","National Nature Science Foundation of China"],"pagination":["297-306"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12863589"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["153(5)"],"pubmed_abstract":["Background
Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors.Methods
The DARE-AF trial (Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation) was a prospective, open-label, parallel-assignment randomiz"],"journal":["Circulation"],"pubmed_title":["Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial."],"pmcid":["PMC12863589"],"funding_grant_id":["2022YFC3601303","BJPSTP-2024-21","82570374","20240484714,20250484963","2024-4-20610"],"pubmed_authors":["Long D","Zhang J","Wang C","Guo X","Liu N","Zei PC","Dai W","Du X","Zuo S","Zhao Z","Liu X","Guo H","Dong J","Tang R","Wang Y","Zhou N","Sang C","Xia S","He L","Xu H","Yang Z","Ma C","Li S","Jiang C","Kong X","Xu Y","Macle L"],"additional_accession":[]},"is_claimable":false,"name":"Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.","description":"Background
Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors.Methods
The DARE-AF trial (Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation) was a prospective, open-label, parallel-assignment randomiz","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-14T21:03:22.943Z","creation":"2026-06-25T03:08:02.493Z"},"accession":"S-EPMC12863589","cross_references":{"pubmed":["41206792"],"doi":["10.1161/CIRCULATIONAHA.125.077447"]}}